Mismatch Between Perceived and Objective HIV Risk Among Individuals Discontinuing PrEP in Homa Bay and Kisii Counties, Kenya

Download Article

DOI: 10.21522/TIJPH.2013.14.01.Art024

Authors : Muchele Polycarp Musee, Collins Ouma

Abstract:

Pre-exposure prophylaxis (PrEP) is highly effective HIV prevention strategy, yet discontinuation may leave individuals vulnerable. Guided by the Health Belief Model, this study examined whether perceived reductions in HIV susceptibility among PrEP discontinuers aligned with objectively assessed epidemiological risk in Homa Bay and Kisii Counties. A cross-sectional analytical study was conducted among 293 clients, of whom 175 reported a decreased perceived risk. Participants were selected using proportionate stratified random sampling across population groups. HIV risk was objectively evaluated using NASCOP-Risk Assessment Screening Tool (RAST). Descriptive statistics, chi-square and Fisher’s exact tests, and logistic regression were applied to examine alignment between perceived and actual risk and identify predictors of high-risk status.  Marked discrepancies were observed between perceived and objective HIV risk. 91.4% of participants who perceived reduced HIV risk were classified as high or substantial risk by RAST. County-underestimation was 94.7% in Homa Bay and 72.0% in Kisii (p < 0.01). Despite reporting reduced perceived risk, many continued to engage in high-risk behaviors, including multiple sexual partnerships (48.4%), condomless sex (28.6%), prior sexually transmitted infections (18.7%), and low consistent condom use (22.5%). County of residence was the only significant predictor of objective high risk (aOR = 0.15; 95% CI: 0.04–0.58); Age, sex, marital status, education, and income were not independently associated. Substantial mismatch between perceived and actual HIV risk exists among PrEP discontinuers, particularly in high-prevalence settings. Strengthened risk assessment, tailored counseling, psychosocial support, and county-specific interventions are critical to prevent premature discontinuation and maintain HIV prevention gains.

References:

[1].   World Health Organization, 2023, HIV statistics, globally and by WHO regions, 2023, Global HIV, Hepatitis and Sexually Transmitted Infections Programs. https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategicinformation/hiv-data-and-statistics

[2].   Tailor, J., Rodrigues, J., Meade, J., Segal, K., Benjamin Mwakyosi, L., 2022, Correlations between oral Pre-Exposure Prophylaxis (PrEP) initiations and policies that enable the use of PrEP to address HIV globally. PLOS Glob Public Health, 2022 Dec 7;2(12):e0001202, Doi: 10.1371/journal.pgph.0001202.

[3].   Whitfield, T. H., John, S. A., Rendhina, A. J., Grov, C., Parsons J. T., 2018, Why I quit pre-exposure prophylaxis (PrEP)? A mixed-method study exploring reasons for PrEP discontinuation and potential re-initiation among gay and bisexual men.  AIDS Behaviour, 2018 Nov;22(11):3566-3575,  Doi: 10.1007/s10461-018-2045-1.

[4].   Zhang, J., Li, C., Xu, J., Hu, Z., Rutstein, S. E., & Tucker, J. D., Ong, J. J., Jiang, Y., Geng, W., et al., 2022, Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. Lancet HIV, 2022 Apr;9(4):e254-e268, Doi: 10.1016/S2352-3018(22)00030-3.

[5].   Stankevitz, K., Grant, H., Lloyd, J., Gomez, G. B., Kripke, K., Torjesen, K., Terris-Prestholt, F., 2020, Oral preexposure prophylaxis continuation,measurementa and reporting. AIDS, 2020 Oct 1;34(12):1801-1811, Doi: 10.1097/QAD.0000000000002598.

[6].   Vanbaelen, T., Rotsaert, A., Jacobs, B. K., Florence, E., Kenyon, C., Vuylsteke, B., Laga, M., Thijs, R., 2022, Why Do HIV Pre-Exposure Prophylaxis Users Discontinue Pre-Exposure Prophylaxis Care? A Mixed Methods Survey in a Pre-Exposure Prophylaxis Clinic in Belgium. AIDS PATIENT CARE and STDs, 2022 Apr;36(4):159-167, Doi: 10.1089/apc.2021.0197.

[7].   Krakower, D., Maloney, K. M., Powell, V. E., Levine, K., Grasso, C., Melbourne, K., Marcus,J,. Mayer Kenneth H, 2019, Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care. International AIDS Society, 2019 Feb;22(2):e25250,  doi: 10.1002/jia2.25250.

[8].   Marcus, J. L., Hurley, L. B., Hare, C. B., Nguyen, D. P., Phengrasamy, T., Silverberg, M. J., Stoltey, J. E,. Volk Johnathan, E., 2017, Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation. Pub Med Central, 540-546, Doi: 10.1097/QAI.0000000000001129.

[9].   Marcus, J. L., Hurley, L. B., Ngoyen, D. P., Silverberge, M. J., Volk Johnathan, E., 2017, Redefining Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis Failures. Clinical Infectious Diseases, 1768 – 1769, Doi: 10.1093/cid/cix593.

[10].  Mboup, A., Behanzin, L., Guedou, F. A., Geraldo, N., Matsetse, E. G., Giguere, L., Aza-Gnandji, M.,et al., 2018, Early antiretroviral therapy and daily pre‐exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study. Journal of International AIDS SOciety, 21(11), 21:e25208, https://doi.org/10.1002/jia2.25208

[11].  Koss, C. A., Havlir, D. V., Ayieka, J., Kwarisiima, D., Kabami, J., Chamie, G., Atukunda, M., Mwinike, J., et al., 2021,  HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda. PLOS Medicine, 2021 Feb 9;18(2):e1003492, Doi: 10.1371/journal.pmed.1003492,  eCollection 2021 Feb.

[12].  Ogolla, M., Nyabiage, O. L., Musingila, P., Gachau, S., Odero, T. M., June, E. O., Ochanda, B., Appolonia, A., Katiku, E., et al., 2023, Uptake and continuation of HIV pre-exposure prophylaxis among women of reproductive age in two health facilities in Kisumu County, Kenya. Journal for International AIDS Society, 023 Mar;26(3):e26069, Doi: 10.1002/jia2.26069.

[13].  Blumenthal, J., Jain, S., Mulvihill, E., Sun, S., Marvin, H., Ellorin, E., Graber, S., Haubrich, R., Morris, S., 2019, Perceived Versus Calculated HIV Risk: Implications for Pre-exposure Prophylaxis Uptake in a Randomized Trial of Men Who Have Sex With Men. J Acquir Immune Defic Synd, 80(2): e23–e29, Doi: 10.1097/QAI.0000000000001888.

[14].  Ongolly, F. K., Dolla, A., Irungu, E. M., Odoyo, J., Wamoni, E., Peebles, K., Mugwanya, K., Mugo, N. R., Bukusi, E. A., Morton, J., Baeten, J. M., O`Malley, G., 2022, “I just decided to stop:” Understanding PrEP discontinuation among individuals initiating PrEP in HIV care centers in Kenya. J Acquir Immune Defic Syndr, 2021 May 1;87(1):e150-e158, Doi: 10.1097/QAI.0000000000002625.

[15].  Gilbert, H. N., Wyatt, M. A., Pisarki, E. E., Mumonge, T. R., Heffron, R., Katabira, E. T., Celum, C. L., Baeten, J. M., Haberer, J. E., Ware Norman, C., 2019, PrEP Discontinuation and Prevention-Effective Adherence: Experiences of PrEP Users in Ugandan HIV Serodiscordant couples. Journal Acquired Immune Deficiency Syndrom, 2019 Nov 1;82(3):265-274, Doi: 10.1097/QAI.0000000000002139.

[16].  Anyasi, H., Idemudia, A., Badru, T., Onyegbule, S., Isang, E., Sanwo, O., Pandey, S.R., Chiegil, R.,et al., 2024, Discontinuation of HIV oral pre-exposure prophylaxis: findings from programmatic surveillance within two general population HIV programs in Nigeria. BMC Public Health. 2024 May 16;24(1):1325, Doi: 10.1186/s12889-024-18808-z.

[17].  Dzenga, T., Moyo, E., Moyo, P., Kamangu, J., Dzinamarira, T., 2023, Factors influencing the retention of clients in oral pre-exposure prophylaxis (PrEP) care at 3 months after initiation in the Omusati region of Namibia. International Journal of Africa Nursing Sciences, Volume 19, 2023, 100623, https://doi.org/10.1016/j.ijans.2023.100623

[18].  Herns, S., Panwala, R., Pfeil, A., Sardinho, M., Rossi, V., Blumenthal, J., & Hill, L., 2023, Predictors of PrEP retention in at risk patients seen at a HIV primary care clinic in San Diego. International Journal of STD and AIDS, 785–790, 2023 Oct;34(11):785-790, Doi: 10.1177/09564624231179276.

[19].  Garofoli, M., Siguier, M., Robineau, O., Valette, M., Phung, B., Bachelard, A., Rioux, C., Gac, S.L., Digumber, M., Pialoux, G., Ghosn, J., Champenois, K., 2024, Incidence and factors associated with PrEP discontinuation in France. Journal of Antimicrobial Chemotherapy, 2024 Jul 1;79(7):1555-1563,  Doi: 10.1093/jac/dkae133.

[20].  Shover, C. L., Shoptaw, S., Javanbakhat, M., Lee, S. J., Bolan, R. K., Cunningham, N. J., Beymer, M., DeVost, M. A., Gorbach Pamina, M., 2020, Mind the Gaps: Prescription coverage and HIV incidence among patients receiving pre-exposure prophylaxis from a large federally qualified health center in Los Angeles, California. PubMed Central, 2730 - 2740. Doi: 10.1007/s10461-019-02493.